{
  "id": 15759172,
  "title": "Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO",
  "url": "https://urgent.news/2026/10/20/pfizer-ends-phase-2-autoimmune-study-lycia-aims-for-227m-ipo",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-20T14:55:11.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/pfizer-ends-phase-2-autoimmune-study-lycia-aims-for-227m-ipo/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Pfizer halts Phase 2 autoimmune trial: The study was testing a program called PF-06835375 in the rare autoimmune disorder primary immune thrombocytopenia. The federal clinical trials database noted the halt was ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}